Anaptysbio (ANAB) Return on Capital Employed (2017 - 2026)
Anaptysbio's (ANAB) quarterly Return on Capital Employed came in at 13.36% in Q1 2026, up 3789.0% YoY from 0.34% in Q1 2025, and down 10.7% on a QoQ basis from 14.96% in Q4 2025.
Anaptysbio (ANAB) Return on Capital Employed (2017 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 10 years of Return on Capital Employed data on file, last reported at 13.36% in Q1 2026.
- Quarterly Return on Capital Employed rose 3789.0% year-over-year to 13.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.36% (up 3789.0% YoY) and the FY2025 annual result came in at 12.42%, up 3962.0% from the prior year.
- Return on Capital Employed fell to 13.36% in Q1 2026, from 14.96% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.96% in Q4 2025 to a low of 43.17% in Q2 2024.
- A 5-year average of 21.51% and a median of 24.53% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 2229 bps — and 2025, when it soared 4090 bps.
- Tracing ANAB's Return on Capital Employed over 5 years: stood at 19.57% in 2022, then plunged by 94 bps to 38.02% in 2023, then soared by 32 bps to 25.94% in 2024, then jumped by 158 bps to 14.96% in 2025, then declined by 11 bps to 13.36% in 2026.
- The last three Return on Capital Employed figures came in at 13.36% (Q1 2026), 14.96% (Q4 2025), and 9.37% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 13.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.36% |
| Dec 31, 2025 | 14.96% |
| Sep 30, 2025 | -9.37% |
| Jun 30, 2025 | -25.10% |
| Mar 31, 2025 | -24.53% |
| Dec 31, 2024 | -25.94% |
| Sep 30, 2024 | -35.39% |
| Jun 30, 2024 | -43.17% |
| Mar 31, 2024 | -40.88% |
| Dec 31, 2023 | -38.02% |
| Sep 30, 2023 | -32.02% |
| Jun 30, 2023 | -28.44% |
| Mar 31, 2023 | -23.44% |
| Dec 31, 2022 | -19.57% |
| Sep 30, 2022 | -20.39% |
| Jun 30, 2022 | -16.39% |
| Mar 31, 2022 | -11.43% |
| Dec 31, 2021 | -10.98% |
| Sep 30, 2021 | 1.90% |
| Jun 30, 2021 | -2.53% |